Avalo Therapeutics (AVTX) vs Prime Medicine (PRME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Avalo Therapeutics (AVTX) has outperformed Prime Medicine (PRME) over the past year, gaining 0.7% versus a loss of 33.6%. Avalo Therapeutics is the larger company by market cap ($728.3 million vs $707.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTX | PRME |
|---|---|---|
| Share price | $13.58 | $3.90 |
| Market cap | $728.30M | $707.37M |
| 1-day change | -0.07% | +11.43% |
| YTD return | -25.22% | +12.39% |
| 1-year return | +0.74% | -33.56% |
| 5-year return | -99.79% | — |
| EPS (TTM) | $-4.31 | $-1.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.27 | $6.65 |
| 52-week low | $12.51 | $2.67 |
| Distance from 52-week high | -44.05% | -41.35% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +224.59% | +82.31% |
| Average volume | 926.15K | 3.32M |
| Shares outstanding | 53.63M | 181.38M |
| Employees | 33 | 146 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVTX has outperformed PRME by 34.3 percentage points over the past year.
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Prime Medicine
PRME stock →Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 146 employees
AVTX vs PRME FAQ
Which is bigger, Avalo Therapeutics or Prime Medicine?
Avalo Therapeutics (AVTX) is larger, with a market capitalization of $728.30M compared with $707.37M for Prime Medicine (PRME).
Which stock has performed better over the past year, AVTX or PRME?
AVTX returned +0.74% over the past 12 months, compared with -33.56% for PRME (price return, excluding dividends). Past performance does not predict future results.
Are Avalo Therapeutics and Prime Medicine in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Avalo Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Prime Medicine.